Drug intelligence / Profile preview

KD2505

Development stage: Preclinical
Lead developer: Kyungdong Pharmaceutical
Modality: Small Molecules

Overview

KD2505 is an improved new drug (incrementally modified drug) being developed by Kyungdong Pharmaceutical for the treatment of diabetes. As an improved new drug in the South Korean regulatory context, it likely represents a modification of an existing pharmaceutical agent—such as a new salt, formulation, or fixed-dose combination—designed to provide clinical advantages over the original product. As of late 2025, the asset is in the discovery stage of development, and specific details regarding its molecular target or mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on KD2505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD2505.

Explore the full profile